Kyverna Therapeutics Names Georg Schett, M.D., and Peter A. Merkel, M.D., MPH, to Scientific Advisory Board

/PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a cell therapy company engineering a new class of therapies for serious autoimmune diseases, today announced...

Related Keywords

Germany ,Erlangen ,Bayern ,Wiesbaden ,Hessen ,Vienna ,Wien ,Austria ,Harvard University ,Massachusetts ,United States ,German ,Petera Merkel ,Dominic Borie ,Georg Schett ,Yale University ,Amgen ,Hospital Harvard Medical School ,Collaborative Research Centre ,Head Of The Department Internal Medicine ,Friedrich Alexander University ,University Of Innsbruck ,German Research Foundation ,Hospital Of The University Pennsylvania ,Scleroderma Clinical Trials Consortium ,University Of Pennsylvania ,National Academy Of Sciences Germany ,Vasculitis Clinical Research Consortium ,University Of Vienna ,Internal Medicine ,Vice President ,Scientific Advisory Board ,Principal Investigator ,Molecular Assessment ,Signatures Characterizing ,National Academy ,Carol Nachman Prize ,Franciscus Blondel Medal ,National Institutes ,Sponsored Vasculitis Clinical Research Consortium ,Scleroderma Clinical Trials ,Massachusetts General ,Harvard Medical ,Refractory Systemic Lupus ,Preliminary Efficacy Data From ,First Four ,Ann Rheum ,Kyverna Therapeutics ,